MLICM
KITE

Metropolitan Life Insurance Company (MetLife)’s Kite Pharma, Inc. KITE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-32,738
Closed -$5.89M – 2565
2017
Q3 		$5.89M Sell
32,738
-298
-0.9% -$41.5K 0.04% 485
2017
Q2 		$3.42M Buy
33,036
+5,852
+22% +$478K 0.02% 772
2017
Q1 		$2.13M Sell
27,184
-783
-3% -$48.4K 0.01% 933
2016
Q4 		$1.25M Hold
27,967
– – 0.01% 1180
2016
Q3 		$1.56M Sell
27,967
-480
-2% -$26.7K 0.01% 1054
2016
Q2 		$1.42M Buy
28,447
+5,165
+22% +$254K 0.01% 1071
2016
Q1 		$1.07M Buy
23,282
+3,093
+15% +$150K 0.01% 1144
2015
Q4 		$1.24M Hold
20,189
– – 0.01% 1073
2015
Q3 		$1.12M Hold
20,189
– – 0.01% 1136
2015
Q2 		$1.23M Buy
+20,189
New +$1.15M 0.01% 1162
2015
Q1 		– Sell
-6,962
Closed -$401K – 2579
2014
Q4 		$401K Sell
6,962
-3,898
-36% -$164K ﹤0.01% 1921
2014
Q3 		$309K Buy
+10,860
New +$269K ﹤0.01% 2061

Metropolitan Life Insurance Company (MetLife)'s KITE Position: Q4 2017 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 32,738 shares — an estimated $5.89M sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KITE in Q3 2014 and held it in 12 quarters. The position peaked at $5.89M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 32,738 Kite Pharma, Inc. shares in Q4 2017, an estimated $5.89M.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 12 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Kite Pharma, Inc. position peaked at $5.89M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2017, filed 15 Feb 2018.